Janux Therapeutics released a new data cut from an ongoing Phase 1 study of JANX007, a T‑cell engager for metastatic castration‑resistant prostate cancer, showing response rates around 30% in the updated cohort but reporting a downward revision from earlier, higher figures. The company also communicated safety and tolerability updates alongside efficacy dynamics. Investors reacted to the updated readout and commentary from Janux leadership; the evolving dataset underscores the challenges of early‑stage development for solid‑tumor T‑cell engagers, where response durability and toxicity management remain critical. Janux said it will continue dose escalation and cohort expansion to define the therapeutic window and next clinical steps.